Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.36 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.31 |
| ▸ | FLT3 | P36888 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.30 |
| ▸ | FYN | P06241 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2915640 | 0.89 | CRBN (0.34) | CRBNCYP3A4MAP3K11 | |
| SCHEMBL478603 | 0.87 | CRBN (0.42) | CRBNCYP3A4BRD4 | |
| SCHEMBL2913314 | 0.86 | CRBN (0.42) | CRBNCYP3A4CYP17A1BRD4 | |
| SCHEMBL2909603 | 0.85 | CRBN (0.42) | CRBNCYP3A4BRD4 | |
| SCHEMBL3105519 | 0.85 | CRBN (0.42) | CRBNCYP3A4BRD4 | |
| SCHEMBL2910784 | 0.83 | CRBN (0.41) | CRBNCYP3A4FYN | |
| SCHEMBL1530679 | 0.83 | CRBN (0.59) | CRBNCYP3A4CYP17A1BRD4 | |
| SCHEMBL2913952 | 0.82 | CRBN (0.40) | CRBNCYP3A4 | |
| SCHEMBL2907834 | 0.80 | CRBN (0.35) | CRBNCYP3A4 | |
| SCHEMBL1530424 | 0.80 | CRBN (0.37) | CRBNCYP3A4FYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2222646-A1 | URACIL OR THYMINE DERIVATIVE FOR TREATING HEPATITIS C | Abbott Laboratories (US) | 2010-09-01 | — | — | EP | disclosed |
| WO-2009039127-A1 | URACIL OR THYMINE DERIVATIVE FOR TREATING HEPATITIS C | ABBOTT LABORATORIES (US) | 2009-03-26 | — | — | WO | disclosed |